November 4, 2013

BIND Awarded the RUSNANOPRIZE 2013 for Innovative Development of Nanomedicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that BIND has been awarded the RUSNANOPRIZE 2013 for Innovative Development by the International Prize Award Committee. This award recognizes BIND for its translation of state-of-the-art nanoparticle technology into clinical-stage development. The award ceremony was held at the Moscow International Forum for Open Innovation in Moscow on November 1, 2013.

"BIND is honored to receive this prestigious award and to be recognized by this world-wide panel of top scientific and business judges," said Scott Minick, BIND's CEO. "We are focused on leveraging BIND's medicinal nanoengineering platform to develop a pipeline of targeted therapeutics, called Accurins, with the potential to create innovative new medicines for patients in need worldwide."

BIND's co-founders, Professor Robert S. Langer Sc.D., Massachusetts Institute of Technology David H. Koch Institute Professor and Omid Farokhzad, M.D., Associate Professor at Harvard Medical School, have also been awarded the RUSNANOPRIZE for their research related to nanoparticle technologies for medical applications.

About the RUSNANOPRIZE

The RUSNANOPRIZE for Innovative Development is awarded each year by the International Prize Award Committee of the Russian Nanotechnology Corporation to researchers whose nanotechnology discoveries and innovations have been applied to production as well as to companies that have successfully implemented them. The members of the International Prize Award Committee are representatives of the scientific and innovative business community who are generally acknowledged to have achieved outstanding results in their fields. More information about the RUSNANOPRIZE can be found at http://www.rusnanoprize.ru/en/

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer. To date in 2013, BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company's expectations regarding BIND-014 and its pipeline of Accurin candidates and upcoming events and presentations.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectation of losses for the foreseeable future; our need for additional funding; uncertainties regarding our development efforts and the outcomes of studies of our products; our reliance on collaborations with other biopharmaceutical companies to develop Accurins based on therapeutic payloads from their current pipelines; our complete reliance on third-party manufacturers and third parties to conduct all our clinical trials and manufacture of drug candidates; our inability to obtain regulatory approval for our existing or future product candidates; unanticipated safety or efficacy concerns; the failure of our drug candidates to achieve market success; our inability to obtain or enforce patent protection for our products; our inability to establish effective sales, marketing and distribution capabilities; our failure to comply with regulatory requirements; the ability of our officers, directors and principal stockholders to control matters submitted to stockholders for approval; and these and the other important factors discussed under the caption "Risk Factors" in our final prospectus filed with the Securities and Exchange Commission, or SEC, on September 20, 2013 relating to our Registration Statement on Form S-1, and our other reports filed with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com

Source: BIND Therapeutics

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 BIND Therapeutics, Inc.